Visceral leishmaniasis with multiple splenic nodular lesions

Aguiar, Lucas Mustafa; Galdino, Gabriela Studart; Farias, Luís Arthur Brasil Gadelha

doi:10.1590/0037-8682-0301-2018

Cited by 3 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Arterial blood gas [16] analysis assesses the adequacy of ventilation, oxygenation, and the acid-base status of the body by measuring the levels of pH, oxygen, carbon dioxide, and bicarbonate in arterial blood.…”

Section: Sr9009 Improved Acute Lung Injury Induced By Sepsismentioning

confidence: 99%

SR9009 Regulates Acute Lung Injury in Mice Induced by Sepsis

Zhang

Cao

et al. 2022

Canadian Respiratory Journal

View full text Add to dashboard Cite

Rev-Erbα is a nuclear heme receptor, transcriptional repressor, and critical component of the molecular clock that drives daily rhythms of metabolism. However, the roles of Rev-Erbα in acute lung injury (ALI) remain unclarified. Hence, the effect of Rev-Erbα on lung injury of sepsis mice is investigated here. The mice sepsis model is established using lipopolysaccharide (LPS) injection, and the expression levels of proinflammatory cytokines, such as tumor necrosis factor alpha (TNF-α), interleukin-6 (IL-6), and interleukin-10 (IL-10) in both RAW246.7 cells and lung tissues, are tested. The inflammatory response is obviously enhanced in LPS-constructed sepsis mice and alleviated by SR9009 agonist treatment. Cell-based experiments reveal that pharmacological activation of Rev-Erbα via SR9009 attenuates the LPS-induced inflammatory response by suppressing TLR4-regulated NF-κB activation. Sepsis induces the increase in W/D ratio; promotes the levels of malondialdehyde (MDA), lactic acid (LA), and superoxide dismutase (SOD); and inhibits the levels of glutathione (GSH), whereas SR9009 treatment could effectively yield beneficial effects on metabolism. In addition, SR9009 treatment ameliorates acidosis and hypoxemia by efficiently decreasing arterial PaCO2 and increasing arterial PaO2, SO2, HCO3–, lactic acid concentration, and blood PH. These findings confirm that SR9009 treatment can alleviate the sepsis-induced lung injury and targeting Rev-Erbα may represent a promising approach for the prevention and management of ALI.

show abstract

Section: Sr9009 Improved Acute Lung Injury Induced By Sepsismentioning

confidence: 99%

SR9009 Regulates Acute Lung Injury in Mice Induced by Sepsis

Zhang

Cao

et al. 2022

Canadian Respiratory Journal

View full text Add to dashboard Cite

show abstract

Spleen and Peritoneal Cavity

Duffy

Castro-Aragon

Tivnan

et al. 2021

Pediatric Ultrasound

View full text Add to dashboard Cite

A 10-Year Retrospective Study on Pediatric Visceral Leishmaniasis in a European Endemic Area: Diagnostic and Short-Course Therapeutic Strategies

Dondi,

Manieri,

Gambuti

et al. 2023

Healthcare

View full text Add to dashboard Cite

Background: Visceral leishmaniasis (VL) is a potentially fatal disease, with an increasing occurrence in northern Italy, affecting children and both immunocompetent and immunocompromised adults. Methods: This retrospective study conducted at the St. Orsola University Hospital of Bologna, Italy, evaluates the characteristics of 16 children (with a median age of 14.3 months) who were hospitalized between 2013 and 2022 for VL. Results: Seventy-five percent of patients presented with a triad of fever, cytopenia, and splenomegaly. An abdominal ultrasound examination revealed splenomegaly and hypoechoic spleen abnormalities in 93.8% and 73.3% of cases, respectively. Five VL cases were complicated by secondary hemophagocytic lymphohistiocytosis. Eleven patients were treated with a single 10 mg/kg dose of Liposomal Amphotericin B (L-AmB), while five received two doses (total of 20 mg/kg); one of the former groups experienced a recurrence. The fever generally decreased 48 h after the first L-AmB dose, and hemoglobin levels normalized within a month. The splenomegaly resolved in approximately 4.5 months. Conclusions: Pediatricians should consider VL in children with fever of an unknown origin, anemia, cytopenia, and splenomegaly. In our experience, abdominal ultrasounds and molecular tests on peripheral blood contributed to diagnosis without the need for bone marrow aspiration. The short-course therapy with two 10 mg/kg doses of L-AmB is safe and effective.

show abstract

Visceral leishmaniasis with multiple splenic nodular lesions

Cited by 3 publications

References 3 publications

SR9009 Regulates Acute Lung Injury in Mice Induced by Sepsis

SR9009 Regulates Acute Lung Injury in Mice Induced by Sepsis

Spleen and Peritoneal Cavity

A 10-Year Retrospective Study on Pediatric Visceral Leishmaniasis in a European Endemic Area: Diagnostic and Short-Course Therapeutic Strategies

Contact Info

Product

Resources

About